Effect evaluation of interleukin-1 receptor antagonist nanoparticles for mesenchymal stem cell transplantation

Table 1 Biochemical parameters of Group A (control), Group B (interleukin-1 receptor antagonist), Group C (mesenchymal stem cells transplantation) and Group D (combination therapy) (mean ± SD)

	Group	Pre-operation	Intra-operation	Time after operation
				D1	D2	D3	D4	D5	W1	W2	W4
ALT (U/L)	A	54.7 ± 22.7	111.4 ± 44.1	167.25 ± 25.8	108.8 ± 25.2	89.3 ± 32.8	63.7 ± 24.6	54.1 ± 13.7	48.3 ± 17.1	38.7 ± 16.3	32.4 ± 4.2
	B	48.9 ± 17.3	127.5 ± 20.8	108.5 ± 21.8a	77.6 ± 18.9a	78.5 ± 16.6a	68.7 ± 10.8	55.6 ± 12.9	51.6 ± 10.7	42.8 ± 11.6	45.6 ± 6.9
	C	52.7 ± 14.7	113.1 ± 23.5	157.8 ± 31.3	118.6 ± 16.7	83.6 ± 19.3	70.5 ± 11.2	58.8 ± 14.9	50.6 ± 7.3	51.7 ± 9.1	44.5 ± 6.9
	D	45.2 ± 7.7	112.6 ± 22.9	75.4 ± 10.1ae	66.1 ± 16.7ae	48.2 ± 11.9ae	55.7 ± 9.3	51.9 ± 10.8	44.7 ± 6.1	35.9 ± 2.6	33.6 ± 4.2
TB (μmol/L)	A	2.9 ± 1.3	24.0 ± 8.5	32.3 ± 7.4	26.2 ± 8.8	17.5 ± 5.1	12.9 ± 3.8	7.9 ± 1.9	5.8 ± 1.9	3.1 ± 1.2	1.9 ± 0.5
	B	2.3 ± 1.5	20.8 ± 7.6	28.3 ± 7.2	19.4 ± 5.7	9.7 ± 2.8	9.2 ± 1.8	8.6 ± 2.2	6.5 ± 0.8	3.6 ± 0.9	2.1 ± 0.5
	C	1.3 ± 0.9	18.9 ± 5.7	27.5 ± 5.3	15.8 ± 4.1a	10.7 ± 2.6	7.3 ± 0.8	5.1 ± 0.8	1.9 ± 0.3a	1.7 ± 0.6	0.98 ± 0.1
	D	1.52 ± 0.73	24.2 ± 4.4	17.1 ± 2.7ace	8.9 ± 3.51ac	5.11 ± 3.3a	2.68 ± 2.03ac	1.96 ± 1.51ac	1.47 ± 0.75ac	1.25 ± 0.7a	0.43 ± 0.05
NH3 (μmol/L)	A	33 ± 5.2	344.5 ± 102.1	267.5 ± 134.6	179 ± 33.6	159.2 ± 41.3	111.7 ± 32.6	88.5 ± 30.7	64.8 ± 7.3	99.3 ± 16.4	69 ± 24.2
	B	39 ± 10.4	318 ± 67.8	206.5 ± 22.1	160.6 ± 18.2	128.8 ± 18.5	92.5 ± 11.3	114.2 ± 25.6	88.5 ± 19.7	73 ± 16	55.6 ± 11.8
	C	59 ± 12.4	335.8 ± 81.5	210.1 ± 21.7	163.5 ± 18.2	92.8 ± 23.3a	121.4 ± 24.5	110.8 ± 53.2	97.2 ± 26.8	48.9 ± 10.4a	57.2 ± 10.5
	D	38 ± 13.5	369.3 ± 104.2	148.7 ± 39.4ace	106.1 ± 23.8ac	81.3 ± 24.2ac	84.6 ± 17.5a	87.7 ± 23.9	62 ± 17.8	42.7 ± 13.3ac	41.7 ± 11.3
ALB (g/L)	A	30.5 ± 4.3	27.7 ± 2.4	26.2 ± 3.0	25.1 ± 2.1	24.4 ± 1.6	25.2 ± 1.9	25.6 ± 1.4	26.3 ± 1.2	26.7 ± 1.7	28.5 ± 2.5
	B	31.4 ± 3.3	28.7 ± 2.6	27.1 ± 1.8	25.7 ± 2.4	25.9 ± 2.7	25.6 ± 1.5	26.9 ± 0.9	26.5 ± 3.2	26.8 ± 3.7	28.8 ± 2.3
	C	28.8 ± 2.8	27.2 ± 2.2	26.6 ± 3.3	24.9 ± 1.8	25.1 ± 1.1	25.8 ± 1.6	26.3 ± 0.8	27.1 ± 4.2	27.9 ± 1.5	30.5 ± 2.1
	D	30.6 ± 3.5	26.7 ± 1.2	25.1 ± 2.2	26.2 ± 2.1	27.7 ± 1.5	30.1 ± 0.9ace	30.7 ± 1.4ace	31.7 ± 2.6	32.2 ± 2.1ace	33.5 ± 2.5

^aP < 0.05 vs Group A;

^cP < 0.05 vs Group B;

^eP < 0.05 vs Group C. ALT and ammonia in Group D were significantly lower than those in Group A (P < 0.05) within 1 to 4 d after combination therapy, and the low level of TB in Group D lasted longer than that in Group A (P < 0.05) and Group B (P < 0.05) from the 1 d to 1 wk. The improvement in ALB in Group D was seen on the second d after treatment; Group B showed a significant reduction in ALT level within 1 to 3 d after interleukin-1 receptor antagonist injection compared with Group A (P < 0.05); MSCs transplantation displayed a slight effect on reducing TB and ammonia level in Group C. MSCs: Mesenchymal stem cells; ALT: Alanine aminotransferase; ALB: Albumin; TB: Total bilirubin.